Back to results
US 2021/0198355 A1Published application
Anti-il-23 antibodies
AssigneeBoehringer Ingelheim International GmbH
InventorsRachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
Claims5
-30. (canceled)
An anti-IL-23p19 antibody or antigen-binding fragment thereof comprising a light chain variable region comprising:
- a) a light chain CDR1 (L-CDR1) sequence of SEQ ID NO:1, 4, 6, 7, 8, 11, 15, 18, 22, 27 or 30;
- b) a light chain CDR2 (L-CDR2) sequence of SEQ ID NO:2, 5, 9, 12, 16, 23, 25, 28 or 31;
- and
- c) a light chain CDR3 (L-CDR3) sequence of SEQ ID NO:3, 10, 13, 14, 17, 24, 26, 29, or 32;
- and a heavy chain variable region comprising:
- d) a heavy chain CDR1 (H-CDR1) sequence of SEQ ID NO:33, 36, 38, 40, 43, 45, 48, 51, 54, 57, 60, 69, 77 or 80;
- e) a heavy chain CDR2 (H-CDR2) sequence of SEQ ID NO:34, 39, 41, 46, 49, 52, 55, 58, 61, 70, 72, 73, 75, 78 or 81;
- and
- f) a heavy chain CDR3 (H-CDR3) sequence of SEQ ID NO:35, 37, 42, 44, 47, 50, 53, 56, 59, 62, 71, 74, 76, 79 or 82.
6 more elements
34-36. (canceled)
Dependencies are inferred from the claim text.